GleamWall
中文EN

MDLN Medline Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 2046386 · Fiscal year ends 12/31

Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin25.7%
Operating margin5.7%
Net margin1.9%
FCF margin6.2%
EBITDA margin9.0%

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets51.7%
Debt / equity1.07x
Current ratio4.04x
Interest coverage2.50x

Cash quality & payout

Operating cash flow / net income4.13x
Accruals ratio—
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-262026Q2*2026-06-272026Q1*2026-03-282025Q4*2025-12-312025Q32025-09-272025Q22025-06-282025Q12025-03-29
Income statement
Revenue$7.86B$7.68B$7.35B$7.79B$7.12B$6.89B$6.64B
Cost of revenue$5.93B$5.47B$5.51B$5.87B$5.24B$4.98B$4.82B
Gross profit$1.93B$2.21B$1.84B$1.91B$1.88B$1.91B$1.82B
SG&A expense$1.26B$1.29B$1.23B$1.26B$1.12B$1.07B$1.07B
Operating income$500.00M$395.00M$422.00M$425.00M$574.00M$642.00M$571.00M
Interest expense$165.00M$168.00M$165.00M$200.00M$248.00M$253.00M$244.00M
Pretax income$386.00M$235.00M$291.00M$206.00M$345.00M$359.00M$338.00M
Income tax$68.00M$96.00M$52.00M$26.00M$23.00M$26.00M$16.00M
Net income$195.00M$60.00M$129.00M$193.00M$318.00M$329.00M$319.00M
EBITDA$759.00M$651.00M$676.00M$686.00M$827.00M$892.00M$818.00M
EPS (basic)0.230.070.16————
EPS (diluted)0.220.070.16————
Weighted avg. shares (diluted)1.32B860.89M824.84M————
Balance sheet
Cash & equivalents$2.32B$2.33B$2.24B$1.94B$955.00M$584.00M$840.00M
Short-term investments$1.29B$350.00M—$0———
Receivables$3.79B$3.66B$3.67B$3.53B———
Inventory$4.81B$4.67B$4.81B$4.77B———
Current assets$12.65B$11.74B$11.18B$10.68B———
PP&E, net$4.73B$4.70B$4.76B$4.78B———
Goodwill$8.07B$8.07B$8.08B$8.08B———
Intangibles$13.38B$13.54B$13.72B$13.89B———
Total assets$40.18B$39.35B$39.01B$38.48B———
Current liabilities$3.13B$2.71B$2.54B$2.49B———
Short-term debt$29.00M$29.00M$77.00M$77.00M———
Long-term debt$12.55B$12.55B$12.49B$12.48B———
Total debt$12.58B$12.58B$12.57B$12.56B———
Total liabilities$20.79B$20.27B$19.66B$19.20B———
Shareholders' equity$11.80B$11.57B$11.27B$10.74B———
Net debt$10.26B$10.25B$10.34B$10.62B———
Cash flow statement
Operating cash flow$1.02B$715.00M$412.00M$229.00M$636.00M$197.00M$682.00M
Capital expenditure$141.00M$111.00M$96.00M$138.00M$101.00M$110.00M$98.00M
Free cash flow$884.00M$604.00M$316.00M$91.00M$535.00M$87.00M$584.00M
Investing cash flow-$980.00M-$461.00M-$96.00M-$138.00M-$101.00M-$143.00M-$92.00M
Financing cash flow-$48.00M-$159.00M-$13.00M$897.00M-$161.00M-$328.00M-$9.00M
Depreciation & amortization$259.00M$256.00M$254.00M$261.00M$253.00M$250.00M$247.00M
Stock-based compensation$29.00M$29.00M$23.00M$27.00M$15.00M$15.00M$19.00M
Share buybacks$0$0$0$0$18.00M$6.00M$9.00M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.